Spatial flexibility in ternary complexes between SRF and its accessory proteins.

Por Treisman, R, Marais, R, Wynne, J
Publicado em 1992

The phosphorylation of protein kinase C as a potential measure of activation.

Por Mitchell, F E, Marais, R M, Parker, P J
Publicado em 1989

Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation.

Por Marais, R, Light, Y, Paterson, H F, Marshall, C J
Publicado em 1995

Casein kinase II phosphorylation increases the rate of serum response factor-binding site exchange.

Por Marais, R M, Hsuan, J J, McGuigan, C, Wynne, J, Treisman, R
Publicado em 1992

A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia

Por Korfi, K., Mandal, A., Furney, S. J., Wiseman, D., Somervaille, T. C. P., Marais, R.
Publicado no Ann Oncol (2015)

BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors

Por Korfi, K, Smith, M, Swan, J, Somervaille, T C P, Dhomen, N, Marais, R
Publicado no Cell Death Dis (2016)

Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation.

Por Mason, C S, Springer, C J, Cooper, R G, Superti-Furga, G, Marshall, C J, Marais, R
Publicado em 1999

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition

Por Turajlic, S., Furney, S. J., Stamp, G., Rana, S., Ricken, G., Oduko, Y., Saturno, G., Springer, C., Hayes, A., Gore, M., Larkin, J., Marais, R.
Publicado em 2014

Cellular senescence in naevi and immortalisation in melanoma: a role for p16?

Por Gray-Schopfer, V C, Cheong, S C, Chong, H, Chow, J, Moss, T, Abdel-Malek, Z A, Marais, R, Wynford-Thomas, D, Bennett, D C
Publicado em 2006

A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs

Por Spooner, R A, Friedlos, F, Maycroft, K, Stribbling, S M, Roussel, J, Brueggen, J, Stolz, B, O'Reilly, T, Wood, J, Matter, A, Marais, R, Springer, C J
Publicado em 2003

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA

Por Gremel, G., Lee, R. J., Girotti, M. R., Mandal, A. K., Valpione, S., Garner, G., Ayub, M., Wood, S., Rothwell, D. G., Fusi, A., Wallace, A., Brady, G., Dive, C., Dhomen, N., Lorigan, P., Marais, R.
Publicado no Ann Oncol (2016)

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

Por Eisen, T, Ahmad, T, Flaherty, K T, Gore, M, Kaye, S, Marais, R, Gibbens, I, Hackett, S, James, M, Schuchter, L M, Nathanson, K L, Xia, C, Simantov, R, Schwartz, B, Poulin-Costello, M, O'Dwyer, P J, Ratain, M J
Publicado em 2006

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies

Por Eisen, T, Marais, R, Affolter, A, Lorigan, P, Robert, C, Corrie, P, Ottensmeier, C, Chevreau, C, Chao, D, Nathan, P D, Jouary, T, Harries, M, Negrier, S, Montegriffo, E, Ahmad, T, Gibbens, I, James, M G, Strauss, U P, Prendergast, S, Gore, M E
Publicado em 2011